Notably, studies have detected aberrant expression of the IL-22 receptor in mantle cell lymphoma (MCL), which may promote cell growth in MCL by modulating various cellular signaling pathwaysThis observation leads to the hypothesis that patients with increased IL-22/IL-22R pathway expression might be at a higher risk for lymphoma (Gelebart et al., 2011). This evidence concerns the gene IL22RA1 and mantle cell lymphoma.